General
Preferred name
REGORAFENIB
Synonyms
BAY 73-4506 monohydrate ()
Stivarga, BAY-73-4506, BAY-734506 monohydrate ()
BAY73-4506 hydrochloride ()
BAY 73-4506 ()
Fluoro-Sorafenib ()
Regorafenib Hydrochloride ()
Regorafenib (BAY 73-4506) ()
A-1112 ()
Regorafenib (monohydrate) ()
Regorafenib (Hydrochloride) ()
BAY-73-4506 ()
BAY-734506 ()
REGORAFENIB ANHYDROUS ()
REGORAFENIB HYDRATE ()
Regorafenib Monohydrate ()
STIVARGA ()
BAY 73-4506 (monohydrate) ()
BAY 73-4506 (hydrochloride) ()
Regorafenib (BAY-734506) Monohydrate ()
Fluoro-Sorafenib, Resihance, Stivarga,BAY 73-4506 ()
Fluoro-sorafenib, Resihance, Stivarga, regorafaenib monohydrate ()
Stivarga, BAY 73-4506 hydrochloride ()
Regorafenib-13C-d3 ()
P&D ID
PD003518
CAS
755037-03-7
835621-07-3
1019206-88-2
2126178-55-8
Tags
probe
natural product
drug
available
Approved by
EMA
FDA
First approval
2012
Drug Status
approved
Drug indication
Metastatic colorectal cancer
Max Phase
Phase 4
Probe info
Probe type
calculated probe
Probe sources
Probe Miner (suitable probes)
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
HALF-LIFE Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); ; M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); ; M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);
ABSORPTION Cmax = 2.5 μg/mL;; Tmax = 4 hours; ; AUC = 70.4 μg*h/mL; ; Cmax, steady-state = 3.9 μg/mL;; AUC, steady-state = 58.3 μg*h/mL;; The mean relative bioavailability of tablets compared to an oral solution is 69% to 83%.
DESCRIPTION Regorafenib is an inhibitor of multiple membrane-bound and intracellular kinases. Although the drug is approved it must carry a Boxed Warning alerting patients and clinicians that severe and fatal liver toxicity was observed in some patients in regorafenib clinical studies. Regorafenib is a Type-2 kinase inhibitor. (GtoPdb)
DESCRIPTION inhibitor of BRAF, RET, KIT, and VEGFR2 (Informer Set)
DESCRIPTION Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (PKIDB)
Cell lines
14
Organisms
2
Compound Sets
32
AdooQ Bioactive Compound Library
A10250
Axon Medchem Screening Library
1678
Cayman Chemical Bioactives
18498
25486
ChEMBL Approved Drugs
CHEMBL1946170
ChEMBL Drugs
CHEMBL1946170
Clinical kinase drugs
Concise Guide to Pharmacology 2017/18
5891
Concise Guide to Pharmacology 2019/20
5891
Concise Guide to Pharmacology 2021/22
5891
Concise Guide to Pharmacology 2023/24
5891
Drug Repurposing Hub
DrugBank
DB08896
DrugBank Approved Drugs
DB08896
DrugCentral
4654
DrugCentral Approved Drugs
4654
DrugMAP
DMHSY1I
DrugMAP Approved Drugs
DMHSY1I
EU-OPENSCREEN Bioactive Compound Library
EOS101246
Guide to Pharmacology
5891
Informer Set
628613
JUMP-Target 1 Compound Set
11167602
LINCS compound set
10225-101
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1946170
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL1946170
MedChem Express Bioactive Compound Library
HY-10331
HY-10331A
HY-13308
NCATS Inxight Approved Drugs
24T2A1DOYB
NIH Approved Oncology Drugs
PKIDB
Probe Miner (suitable probes)
P34913/519928
ReFrame library
Selleckchem Bioactive Compound Library
BAY-73-4506
regorafenib-monohydrate
regorafenib-hydrochloride
TargetMol Bioactive Compound Library
T1792
T8402
External IDs
55
Properties
(calculated by RDKit )
Molecular Weight
482.08
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
3
cLogP
5.69
TPSA
92.35
Fraction CSP3
0.1
Chiral centers
0.0
Largest ring
6.0
QED
0.41
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
BRAF
KDR
KIT
RET
VEGFR
PDGFR
Raf-1
VEGFR1
VEGFR2
ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK
RTK inhibitor
DDR2
FLT1
FLT4
PDGFRA
PDGFRB
FGFR1
FGFR2
TEK
NTRK1
EPHA2
RAF1
MAPK11
FRK
ABL1
FGFR
Tie
Autophagy,c-Kit,c-RET,PDGFR,Raf,VEGFR
c-Kit,c-RET,PDGFR,Raf,VEGFR
Compound status
FDA
Targets
KDR,RET,RAF1
Pathway
Angiogenesis
Tyrosine Kinase/Adaptors
Apoptosis
MAPK
Chromatin/Epigenetic
Autophagy
MAPK/ERK Pathway
Protein Tyrosine Kinase/RTK
MOA
c-Kit
c-RET
Raf
FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor
Indication
colorectal cancer, gastrointestinal stromal tumors (GIST)
Source data